- 专利标题： PREVENTION OF ADVERSE EFFECTS CAUSED BY CD3 SPECIFIC BINDING DOMAINS
-
申请号： EP20209362.1申请日： 2011-10-27
-
公开(公告)号： EP3831386A1公开(公告)日： 2021-06-09
- 发明人: Zugmaier, Gerhard , Nagorsen, Dirk , Scheele, Juergen
- 申请人： Amgen Research (Munich) GmbH
- 申请人地址： DE 81477 München Staffelseestrasse 2
- 代理机构： Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
- 优先权： US41222910 P 20101110
- 主分类号： A61K31/573
- IPC分类号： A61K31/573 ; A61K39/395 ; C07K16/28
摘要：
The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.
信息查询
